If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
572.00    33.00 (6.12%)
Bid:
569.00
Ask:
570.00
Spread: 1.00 (0.176%)
Market Cap: £1.55b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Directorate Change

24 Jun 2014 07:00

RNS Number : 3280K
Chemring Group PLC
24 June 2014
 



 FOR IMMEDIATE RELEASE 24 JUNE 2014

 

CHEMRING GROUP PLC

 

Directorate change

 

Michael Flowers appointed Group Chief Executive

 

Chemring Group PLC ("Chemring" or "the Group") announces that Michael Flowers has been appointed Group Chief Executive with immediate effect. Michael joined Chemring in 2006 and prior to today's appointment was Group Director, Countermeasures and a member of Chemring's Executive Committee.

 

Michael Flowers has spent 13 years in senior management positions within the defence industry. He previously served as an officer in the Australian Army for 22 years and was a graduate of the Australian Command and Staff College and the British Royal Military College of Science. After leaving the army, he was a senior manager at BAE Systems from 2001 to 2006, in programme and project management roles.

 

From 2006, he was Managing Director, Chemring Australia, where he established a state of the art countermeasures manufacturing facility and delivered substantial growth in the defence portfolio. In 2013, he was appointed Group Director, Munitions, with responsibility for Chemring's European munitions business. Michael led the successful sale of the European munitions business following the 2013 strategic review, working closely with Chemring's Board and advisers to negotiate and complete the disposal in May 2014.

 

Mark Papworth has stepped down from the Board of Chemring with immediate effect. 

 

Peter Hickson, Chairman of Chemring, said:

 

"Michael Flowers has a proven track record, both within the international defence industry and within Chemring, where he led our Australian business through a successful period of growth and, more recently, managed the complex disposal process of the European munitions business. Michael is extremely knowledgeable about our markets and is well qualified to lead Chemring as we capitalise on our world leading technologies in Countermeasures, Sensors & Electronics and Energetic Systems.

 

Much has been achieved during Mark Papworth's tenure, including a significant reorganisation and refocusing of the Group and a substantial reduction in the cost base and we are grateful for his leadership during this period.

 

We are now moving from a period of critical and significant change to one where we must take maximum advantage of the stronger platform that has been created. To achieve this, a different set of skills is required in the role of Chief Executive, in particular extensive knowledge and understanding of the defence markets in which we operate."

 

Michael Flowers has a beneficial shareholding of 80,680 Chemring shares.

 

There is no further information to be disclosed pursuant to paragraph 9.6.13R of the UK Listing Rules in relation to Michael Flowers' appointment as a director of Chemring.

 

Ends

 

 

 

 

For further information, contact:

 

Chemring Group PLC 01489 881 880

Peter Hickson, Chairman

Steve Bowers, Finance Director

Rupert Pittman, Group Director of Communications and Investor Relations

 

MHP Communications 020 3128 8100

Andrew Jaques

John Olsen

James White

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADDGDLSBDBGSX
Date   Source Headline
7th Mar 20167:00 amRNSAPPOINTMENT OF NON-EXECUTIVE DIRECTOR
1st Mar 20165:26 pmRNSCorrection Re Holding in Company
1st Mar 20161:24 pmRNSTotal Voting Rights
26th Feb 201610:23 amRNSHolding(s) in Company
24th Feb 20168:48 amRNSResult of Rump Placing
23rd Feb 20163:03 pmRNSResults of Rights Issue
23rd Feb 201612:40 pmRNSHolding(s) in Company
19th Feb 20163:13 pmRNSDirector/PDMR Shareholding
9th Feb 20168:07 amRNSAdmission of Nil Paid Rights
8th Feb 201611:52 amRNSResult of EGM
4th Feb 201611:26 amRNSDirector/PDMR Shareholding
4th Feb 201611:25 amRNSDirector/PDMR Shareholding
1st Feb 201611:18 amRNSTotal Voting Rights
27th Jan 20167:00 amRNSDirector/PDMR Shareholding
21st Jan 20163:30 pmRNSPublication of Prospectus
21st Jan 20167:00 amRNS£80.8 million Rights Issue
21st Jan 20167:00 amRNSFinal Results
20th Jan 20164:01 pmRNSDirector/PDMR Shareholding
4th Jan 201610:01 amRNSTotal Voting Rights
21st Dec 201511:19 amRNSBlocklisting Update
21st Dec 201511:17 amRNSBlocklisting Interim Review
1st Dec 20159:57 amRNSTotal Voting Rights
25th Nov 20157:00 amRNSPOST-CLOSE STATEMENT
2nd Nov 201511:21 amRNSHolding(s) in Company
27th Oct 20157:00 amRNSTrading Statement
1st Oct 201511:15 amRNSTotal Voting Rights
29th Sep 20152:25 pmRNSHolding(s) in Company
14th Sep 20157:00 amRNSTrading Update
1st Sep 20159:33 amRNSTotal Voting Rights
20th Aug 20153:01 pmRNSHolding(s) in Company
7th Aug 20151:56 pmRNSHolding(s) in Company
3rd Aug 20159:28 amRNSTotal Voting Rights
1st Jul 20152:47 pmRNSTotal Voting Rights
24th Jun 20155:26 pmRNSHolding(s) in Company
23rd Jun 20157:00 amRNSHalf Yearly Report
19th Jun 20158:55 amRNSBlocklisting Update
19th Jun 20157:00 amRNSBlocklisting Interim Review
11th Jun 201510:02 amRNSAdditional Listing
2nd Jun 20157:00 amRNSTotal Voting Rights
1st May 201512:01 pmRNSTotal Voting Rights
10th Apr 201511:59 amRNSTotal Voting Rights
19th Mar 20152:21 pmRNSResult of AGM
19th Mar 20157:00 amRNSAGM Statement
2nd Mar 20151:41 pmRNSTotal Voting Rights
2nd Feb 20151:16 pmRNSTotal Voting Rights
27th Jan 20154:10 pmRNSDirector/PDMR Shareholding
27th Jan 20154:09 pmRNSDirector/PDMR Shareholding
27th Jan 20154:08 pmRNSDirector/PDMR Shareholding
27th Jan 201512:25 pmRNSDirector/PDMR Shareholding
27th Jan 201512:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.